Dinaciclib
Plasma Cell Myeloma
National Cancer Institute (NCI)Small moleculePhase 2Dormant
B
63/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 48/ 100
- Competitive Position
- 95/ 100
Competitive context
475 Active assets in the Plasma Cell Myeloma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Hyaluronidase Fihj Massachusetts General Hospital | Phase 4 | BBB |
Filanesib PETHEMA Foundation | Phase 2 | BBB |
Vincristine Sulfate Roswell Park Cancer Institute | Phase 3 | BBB |
Cyclosporin A Seoul National University Hospital | Phase 3 | BBB |
Anti-Human T-Lymphocyte Immunoglobulin, Rabbit University of Birmingham | Phase 4 | BBB |
View all 50 →
Same molecule, other indications
Dinaciclib is also rated in:
chronic lymphocytic leukemia/small lymphocytic lymphomaDormant
B
Indicative · Phase 3
58 / 100
View asset →Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →